This I believe is why
$Bionomics(BNOX.US$ Bionomics Has Initiated Patient Screening For The Phase 3 AFFIRM-1 Trial Evaluating The Safety And Efficacy Of BNC210 For The Acute, As-needed Treatment Of Social Anxiety Disorder, Topline Results Are Expected In Q3 2025
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
OneNightOnly : Phase 3 should be a very good news
Trytosaveabit OP OneNightOnly : Yup! But it’s a way off for topline data! But there will be updates before that
104088546 : Going down
Trytosaveabit OP 104088546 : Yup! Figured it would! But it did go up 50%+
104088546 : untill 1.3
104088546 : should be able to reach
Trytosaveabit OP 104088546 : Maybe? Have to see how overall market sentiment GL